ethyl 4-[6-methoxy-1'-(2-phenoxyethyl)-4,9-dihydrospiro[β-carboline-1,3'-pyrrolidin]-2(3H)-yl]butanoate | 853018-69-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: ethyl 4-[6-methoxy-1'-(2-phenoxyethyl)-4,9-dihydrospiro[β-carboline-1,3'-pyrrolidin]-2(3H)-yl]butanoate
• 英文别名: ethyl 4-[6-methoxy-1'-(2-phenoxyethyl)spiro[4,9-dihydro-3H-pyrido[3,4-b]indole-1,3'-pyrrolidine]-2-yl]butanoate
• CAS: 853018-69-6
• 化学式: C₂₉H₃₇N₃O₄
• 分子量: 491.63
• InChiKey: KKAKQSIUYYMXOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  67
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 4-[6-methoxy-1'-(2-phenoxyethyl)-4,9-dihydrospiro[β-carboline-1,3'-pyrrolidin]-2(3H)-yl]butanoate 在 sodium hydroxide 、 水 作用下， 以 乙醇 为溶剂， 以35%的产率得到4-[6-methoxy-1'-(2-phenoxyethyl)-4,9-dihydrospiro[β-carboline-1,3'-pyrrolidin]-2(3H)-yl]butanoic acid
  参考文献：
  名称：

  [EN] TETRAHYDROSPIRO-BETA-CARBOLINE-1,3 '-PYRROLIDINE DERIVATIVES AND THEIR USE IN GHSR-RELATED DISORDERS
  [FR] NOUVELLES CARBOLINES-BETA EN TANT QU'ANTAGONISTES DE RECEPTEUR DE SECRETAGOGUE D'HORMONE DE CROISSANCE

  摘要：

  公开号：

  WO2005048916A3

文献信息

• Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists
  申请人：Crossley Roger

  公开号：US20050288316A1

  公开（公告）日：2005-12-29

  The present invention relates to compounds of Formula (I): wherein R 3 -R 8 , X, and Y are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of a GHSR receptor-related disorder. Examples of such disorders are obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome Prader-Willi syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, acromegaly and cancer, in particular breast, lung, prostate, thyroid and endocrine pituary carcinomas.

  本发明涉及式（I）的化合物：其中R3-R8，X和Y如本文所述，制备该化合物的方法，包含该化合物的药物组合物，以及在预防或治疗与GHSR受体相关的疾病中使用该化合物和组合物。此类疾病的例子包括肥胖症和相关疾病，如2型糖尿病，血脂异常和代谢综合征，普拉德-威利综合征，心血管疾病，如动脉粥样硬化、心绞痛、心肌梗死和中风，肢端肥大症和癌症，特别是乳腺癌、肺癌、前列腺癌、甲状腺癌和内分泌腺垂体癌。
• SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1136492A1

  公开（公告）日：2001-09-26

  The present invention relates to a sulfonamide compound of the formula (I): wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy suppressing action.

  本发明涉及一种式 (I) 的磺酰胺化合物： 其中各符号如说明书中所定义的磺酰胺化合物、其盐和含有该化合物的药物组合物。该化合物可作为预防和治疗基于降血糖作用的疾病和基于 cGMP-PDE 抑制作用、平滑肌松弛作用、支气管扩张作用、血管扩张作用、平滑肌细胞抑制作用和过敏抑制作用的疾病的有效药物。
• US6573274B1
  申请人：——

  公开号：US6573274B1

  公开（公告）日：2003-06-03
• US6890934B2
  申请人：——

  公开号：US6890934B2

  公开（公告）日：2005-05-10
• [EN] NOVEL BETA-CARBOLINES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR (GHSR) ANTAGONISTS<br/>[FR] NOUVELLES CARBOLINES-BETA EN TANT QU'ANTAGONISTES DE RECEPTEUR DE SECRETAGOGUE D'HORMONE DE CROISSANCE
  申请人：BIOVITRUM AB

  公开号：WO2005048916A2

  公开（公告）日：2005-06-02

  The present invention relates to compounds of Formula (I): Formula (I) wherein R3-R8, X, and Y are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of a GHSR receptor-related disorder. Examples of such disorders are obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome Prader-Willi syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, acromegaly and cancer, in particular breast, lung, prostate, thyroid and endocrine pituary carcinomas.